Clinical trials: Inflammatory
Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
This was a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab plus standard-of-care (SOC) compared with placebo plus SOC in patients with COVID-19-induced pneumonia…
- Trial name
- CAN-COVID (NCT04362813)
- Testing
- Canakinumab
- Where
- 39 sites in United States, France and 4 more
- Volunteers
- 454 people
- Sponsor
- Novartis Pharmaceuticals
Crohn Disease
A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease
The main purpose of this study is to record the use of Infliximab (IFX) in the treatment of Chinese children with Crohn's disease (CD) in routine clinical practice and to summarize the clinical efficacy and safety of IFX in the…
- Trial name
- NCT04312659
- Testing
- Infliximab
- Where
- 5 sites in China
- Volunteers
- 38 people
- Sponsor
- Johnson & Johnson (China) Investment Ltd.
Non-inflammatory Arthritis
Does Implant Design Improve Postoperative Flexion?
This study will evaluate whether design features of one implant design allows more knee bend than the other. Patients will have 1 design in the left knee and 1 design in their right knee.
- Trial name
- NCT00380861
- Testing
- Total knee replacement using the PFC Sigma RPF knee implant., Total knee replacement using the PFC Sigma RP knee implant
- Where
- 4 sites in United States
- Volunteers
- 93 people
- Sponsor
- DePuy Orthopaedics
Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
The objective of this registry is to compare outcomes of risankizumab-exposed pregnancies with those of pregnancies that were not exposed to risankizumab among women with plaque psoriasis, psoriatic arthritis (PsA), Crohn's…
- Trial name
- NCT04846959
- Testing
- Risankizumab, Comparator
- Where
- 2 sites in United States
- Volunteers
- 818 people
- Sponsor
- AbbVie
Colitis, Ulcerative
BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis
This trial has two sequentially enrolling parts with different objectives. The primary objectives of this trial are to prove the concept of clinical activity of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active…
- Trial name
- NCT03482635
- Testing
- Spesolimab
- Where
- 54 sites in United States, Austria and 10 more
- Volunteers
- 98 people
- Sponsor
- Boehringer Ingelheim
Gastric Ulcers, Duodenal Ulcers
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD), compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of non-steroidal…
- Trial name
- NCT01452750
- Testing
- TAK-438, Lansoprazole
- Where
- 102 sites in Japan
- Volunteers
- 642 people
- Sponsor
- Takeda
Ulcerative Colitis
A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice
The primary purpose of this study is to evaluate the efficacy of filgotinib in establishing clinical remission at Week 10 or 22.
- Trial name
- NCT06964113
- Testing
- Filgotinib Maleate
- Where
- 19 sites in South Korea
- Volunteers
- 94 people
- Sponsor
- Eisai Korea Inc.
Crohn's Disease
A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease
The primary objective of the clinical trial is the assessment of the acceptability of the new Pentasa formulation - PentasaR Sachets in comparison with the reference PentasaR tablets 500 mg in children with Crohn's disease.
- Trial name
- NCT00225810
- Testing
- Crohn's Disease
- Where
- 2 sites in Czechia
- Volunteers
- 50 people
- Sponsor
- Ferring Pharmaceuticals
Dyslipaemia, Atherosclerosis Risk
Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in Spain
The present project is aimed at determining the prevalence of LDL-C <130 mg/dl with hsCRP ≥2mg/l, and of HDL-C < 40 mg/dl in Spain together with the estimation of cardiovascular risk, to analyze the contribution of measuring…
- Conditions
- Dyslipaemia, Atherosclerosis Risk, Increased hsCRP, Inflammatory and Oxidative Status in the Spanish Population
- Trial name
- DARIOS (NCT00998062)
- Where
- 11 sites in Spain
- Volunteers
- 30,181 people
- Sponsor
- AstraZeneca
Ankylosing Spondylitis
Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis
This study assessed the clinical Assessment of SpondyloArthritis international Society (ASAS) 20 response to secukinumab and evaluated to which extent concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment can be…
- Trial name
- ASTRUM (NCT02763046)
- Testing
- Secukinumab (AIN457) 150 mg s.c.
- Where
- 39 sites in Germany
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease
Evaluation of the safety and the immune response induced by active immunization through a TNFa kinoid in patients with Crohn's disease.
- Trial name
- NCT00808262
- Testing
- TNFa Kinoid
- Where
- 6 sites in South Africa, Switzerland
- Volunteers
- 21 people
- Sponsor
- Neovacs
Atherosclerosis
Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)
This will be an exploratory, open-label, single sequence, two part study (Part A and an optional Part B). The aim of this study will be to assess whether systemic inhibition of Lipoprotein associated phospholipase A2 (Lp-PLA2) in…
- Trial name
- NCT02058641
- Testing
- Darapladib
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- GlaxoSmithKline
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Ulcerative Colitis
Real World Study Of The Clinical Profile And Treatment Outcomes Of Advanced Therapies For Ulcerative Colitis In Portugal
This study aims to characterize the Portuguese population of patients with moderate-to-severe UC receiving advanced therapies, by describing clinical and sociodemographic characteristics, and remission outcomes .
- Trial name
- READ-UC (NCT04156672)
- Sponsor
- Pfizer
Sub-healthy, Hyperlipidemia
The Exploratory Study About the Effect of Using Double Filtration Plasmapheresis (DFPP) Removing Inflammatory Cytokines, Lipids and Toxic Metal Ions in Peripheral Blood in Adults
This study investigates whether using Double Filtration Plasmapheresis (DFPP) could improve the overall health of adults through removing inflammatory cytokines, lipids and toxic metal ions from peripheral blood.
- Conditions
- Sub-healthy, Hyperlipidemia, Toxic Metal Ions Accumulation
- Trial name
- NCT06224296
- Testing
- DFPP
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Crohn's Disease
Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease
The primary objectives of the study are: To evaluate the safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease（CD） To evaluate the clinical efficacy of MT-1303 in subjects with moderate to…
- Trial name
- NCT02378688
- Testing
- MT-1303
- Where
- 11 sites in Czechia, France and 9 more
- Volunteers
- 78 people
- Sponsor
- Tanabe Pharma Corporation
Psoriasis, Arthritis
Safety and Efficacy of BFH772 in Psoriasis Patients
This study will determine the efficacy of topical BFH772 in psoriasis patients and the safety after multiple dosing.
- Trial name
- NCT00987870
- Testing
- BFH772, calcipotriol/betamethasone
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive…
- Trial name
- DIVERSITY1 (NCT02914561)
- Testing
- Filgotinib
- Where
- 513 sites in United States, Argentina and 39 more
- Volunteers
- 1,372 people
- Sponsor
- Lakefront Biotherapeutics NV
Inflammatory Bowel Disease, Perianal Fistula
Perianal Fistula (PAF) Validation and Burden of Illness Study
The purpose of this study is to gain a better understanding of the disease burden and unmet need of perianal fistulas within Crohn's disease (CD) in Ontario.
- Conditions
- Inflammatory Bowel Disease, Perianal Fistula, Crohns Disease
- Trial name
- NCT03981939
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 3,032 people
- Sponsor
- Takeda
Crohn's Disease
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely…
- Trial name
- STARSCAPE-1 (NCT07184931)
- Testing
- Duvakitug
- Where
- 461 sites in United States, Argentina and 34 more
- Volunteers
- 980 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.